Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/30—Oestrogens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
  • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4866—Organic macromolecular compounds

Definitions

• the present invention relates to pharmaceutical compositions having uniform drug distribution and potency utilizing lasofoxifene as an active ingredient and containing a silicon dioxide to reduce loss of the active ingredient during the manufacturing process. Methods for use in the manufacture of such compositions are also disclosed.
• U.S. Pat. No. 5,552,412 describes a class of potent and orally active selective estrogen receptor modulators (SERMS) (e.g., derivatives of tetrahydronaphthalen-2-ol) which are useful in the treatment or prevention of breast cancer, osteoporosis, obesity, cardiovascular disease, hypercholesterolemia, endometriosis and prostatic disease.
• SERMS selective estrogen receptor modulators
• These particular SERMS are of interest due to their improved oral bioavailability over current commercially available SERMS (e.g. raloxifene).
• the SERMS described in U.S. Pat. No. 5,552,412 are very potent thus allowing for low dosage forms.
• compositions at the lower dose range presents a challenge in maintaining consistent potency and uniformity in the drug product manufacturing process.
• loss of active ingredient from adherence to or absorption onto metal surfaces to which the active SERM is exposed during the blending step e.g., contact with metal blender blades and vessel surfaces.
• a manual brushing step is neither efficient nor desirable in a production scale environment.
• Liquid processes can minimize the drug loss issues during drug product manufacturing; however, compounds that are sensitive to oxidation (e.g., tetrahydronaphthalen-2-ol derivatives) make liquid processes very difficult to perform without degradation of the active ingredient. Therefore, there is a need for an improved formulation and process that would minimize adherence of active ingredients onto metal surfaces during the manufacture of medicaments, in particular, those having a low dosage content.
• the present invention provides a pharmaceutical composition having a core containing about 0.3 to about 14.0 w/w % of cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the compound or the prodrug, about 3.0 w/w % of a disintegrant, about 0.5 w/w % of a glidant, about 1.0 w/w % of a lubricant and about 77.0 w/w % to about 91.0 w/w % of a diluent/filler, and an aqueous coating comprising about 1.5 w/w % of a polymer, about 0.9 w/w % of an opacifier, about 0.4 w/w % of a plasticizer, about 1.5 w/w %
• the present invention also provides an encapsulated pharmaceutical composition having as an active ingredient, about 0.3 to about 14.0 w/w % cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the compound or the prodrug, about 3.0 w/w % of a disintegrant, about 0.5 w/w % of a glidant, about 1.0 w/w % of a lubricant and about 81.0 w/w % to about 95.0 w/w % of a diluent/filler.
• the present invention provides a method for manufacturing a pharmaceutical composition having uniform drug distribution and potency.
• the method includes (in the following order) the steps of: (1) blending silicon dioxide and at least one pharmaceutically acceptable excipient, carrier or diluent in a high shear granulator for an appropriate amount of time (about 5 minutes) to produce a blended mixture; (2) adding an active ingredient to the granulator and blending for an additional period of time (about 10 to about 15 minutes) to form an active blend; (3) transferring the active blend from the granulator to a blender; (4) optionally, adding one or more additional pharmaceutically acceptable excipients, carriers or diluents to the active blend; and (5) blending for a suitable period of time (about 5 minutes) to form a pharmaceutical composition having uniform distribution of the active ingredient and uniform potency.
• the resultant blended composition may then be processed further into a desired unit dosage form.
• the active ingredient is present in an amount from about 0.01 to 10.0 mg per unit dose (preferably from about 0.05 to about 5.0 mg, more preferably from about 0.05 to about 4.0 mg, even more preferably from about 0.1 to about 3.5 mg, and most preferably from about 0.1 to about 2.5 mg per unit dose) and the silicon dioxide is present in an amount from about 0.1 to about 2% by weight of the unit dosage form (more preferably from about 0.15 to about 1.0% by weight of the unit dosage form and most preferably from about 0.25 to about 0.75% by weight of the unit dosage form).
• a pharmaceutical composition is provided that is prepared using the method described above.
• a low dosage pharmaceutical composition is provided that comprises an active ingredient (preferably lasofoxifene), a silicon dioxide, and at least one pharmaceutically acceptable excipient, carrier, or diluent wherein the active ingredient is present in an amount less than 4.0% w/w active ingredient (more preferably ⁇ about 0.01% w/w active ingredient and ⁇ 4% w/w active ingredient, even more preferably ⁇ about 0.01% w/w active ingredient and ⁇ about 3.5% w/w active ingredient, most preferably ⁇ about 0.1% w/w active ingredient and ⁇ about 2.5% w/w active ingredient) and the silicon dioxide is present in an amount from about 0.1 to about 2 weight percent.
• a low dosage immediate release pharmaceutical composition comprising a core containing, as an active ingredient, about 0.3 to about 0.7 w/w % cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the compound or the prodrug, about 3.0 w/w % of a disintegrant, about 0.5 w/w % of a glidant, about 1.0 w/w % of a lubricant and about 91.0 w/w % of a diluent/filler, and an aqueous coating comprising about 1.5 w/w % of a polymer, about 0.9 w/w % of an opacifier, about 0.4 w/w % of a plastisizer,
• a medicament is provided that is prepared by the method described above into a unit dosage form, in particular a low dosage form.
• uniform distribution refers to a blended mixture, which meets the FDA criteria (Guidance for Industry ANDA's: Blend Uniformity Analysis, published August 1999) of 10 individual blend samples achieving 90-110% potency of the theoretical strength with an RSD of ⁇ 5% for all blend samples.
• uniform potency refers to a blended mixture that maintains a drug substance activity level greater than or equal to about 90% throughout the manufacturing process.
• phrases “pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
• active ingredient refers to a therapeutically active compound, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates and solvates of the compound and the prodrugs.
• ⁇ or “suitable period of time” refers to the period of time necessary to achieve a desired effect or result.
• a mixture may be blended until a potency distribution is reached that is within an acceptable qualitative range for a given application or use of the blended mixture.
• unit dose or “unit dosage” refers to a physically discrete unit that contains a predetermined quantity of active ingredient calculated to produce a desired therapeutic effect.
• the unit dose or unit dosage may be in the form of a tablet, capsule, sachet, etc. referred to herein as a “unit dosage form.”
• immediate release refers to pharmaceutical dosage forms that provide release immediately following drug administration.
• timed release refers to pharmaceutical dosage forms that prevent drug release after drug administration until a certain amount of time has passed.
• sustained release refers to pharmaceutical dosage forms that provide substantially continuous release over a predetermined time period.
• the present invention provides a pharmaceutical composition having a core containing about 0.3 to about 14.0 w/w % of cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of-the compound or the prodrug, about 3.0 w/w % of a disintegrant, about 0.5 w/w % of a glidant, about 1.0 w/w % of a lubricant and about 77.0 w/w % to about 91.0 w/w % of a diluent/filler, and an aqueous coating-comprising about 1.5 w/w % of a polymer, about 0.9 w/w % of an opacifier, about 0.4 w/w % of a plasticizer, about 1.5 w/w
• the present invention also provides an encapsulated pharmaceutical composition having as an active ingredient, about 0.3 to about 14.0 w/w % cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the compound or the prodrug, about 3.0 w/w % of a disintegrant, about 0.5 w/w % of a glidant, about 1.0 w/w % of a lubricant and about 81.0 w/w % to about 95.0 w/w % of a diluent/filler.
• the present invention provides a process for maintaining uniformity and potency during the manufacture of a pharmaceutical composition containing a highly potent active ingredient.
• the process includes a means for reducing the loss of active ingredients that adhere to the metal surfaces of equipment during the manufacturing process of a pharmaceutical composition or medicament.
• Active ingredients of particular interest are SERM compounds of Formula (I) below:
• E and B are independently selected from CH and N; R 1 is hydrogen, hydroxy, fluoro or chloro; and G is
• a prodrug thereof or a pharmaceutically acceptable salt, hydrate or solvate of the compound or the prodrug.
• Preferred compounds include cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol; ( ⁇ )-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol; cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol; cis-1-[6′-pyrrolodinoethoxy-3′-pyridyl]-2-phenyl-6-hydroxy-1,2, 3,4-tetrahydrohaphthalen-1-(4′-pyrrolidinoethoxyphenyl)-2-(4′′-
• a more preferred compound is cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the compound or the prodrug.
• the compounds of Formula (I) are very potent compounds thus requiring special handling to reduce operator exposure during the manufacturing process.
• the compounds of Formula (I) may be sensitive to oxidation, which may limit or preclude the use of liquids and materials containing peroxide contaminants (e.g., polyethylene glycols) during drug product manufacture.
• Conventional methods for manufacturing tablets typically use a wet or dry granulation step prior to compression into a tablet.
• the types of mixing processes for a dry granulation can be divided into two broad categories: (i) batch, and (ii) continuous.
• the most prevalent type used in the pharmaceutical industry is the batch type, which mixes a sub-lot or total lot of a formulation at one time.
• particle movement is achieved by rotation of the entire mixer shell or body.
• Blend/Mill/Blend dry granulation process the following steps are generally employed:
• [0028] (1) pass an active ingredient through an appropriately sized sieve and then blend in a blender (e.g., twin shell blender) for an appropriate period of time to produce a blended mixture;
• a blender e.g., twin shell blender
• the conventional blend/mill/blend dry process presents several disadvantages. For example, it is labor intensive, the dusty operation increases the operator's exposure to the active ingredient, and the increased exposure to metal surfaces increases the risk of potency loss. In addition, segregation problems are observed with mixtures having wide particle size distribution and large differences in particle densities. Tumbling-type blenders are generally not suitable for fine particulate systems because there may not be enough shear to reduce particle agglomeration and, if the powders are free flowing, serial dilution may be required for the addition of low dose active ingredients.
• High-speed granulators are stationary shell mixers with a large mixer-scraper blade that mixes the ingredients, eliminates dead spots in the mixer container and presents the mixer contents to a high-speed chopper blade, which intimately mixes the ingredients.
• the equipment is extremely rapid and provides intimate solids/solids mixing.
• a vertical type of mixer e.g., equipment available from L ⁇ DIGE Industries, Paderborn, Germany; NIRO Inc., Columbia, Md.; and DIOSNA Dierks & Soehne GmbH, Osnabrueck, Germany
• rotating mixing impellers mix the particles centrifugally at a high speed causing a highly fluidized vortex of material.
• a chopper rotating at a very high speed, interrupts the ascending circulation of the material and diverts the product into a vertical flow.
• suitable high-speed granulators include SpectrumTM and Pharma MatrixTM (both available from Niro Pharma Systems, Columbia, Md.).
• the present invention provides a dry process that comprises the following steps:
• the final pharmaceutical composition is processed into a unit dosage form (e.g., tablet, capsule or sachet) and then packaged for distribution.
• a unit dosage form e.g., tablet, capsule or sachet
• the processing step will vary depending upon the particular unit dosage form. For example, a tablet is generally compressed under pressure into a desired shape and a capsule or sachet employs a simple fill operation. Those skilled in the art are well aware of the procedures used for manufacturing the various unit dosage forms.
• the active blend generally includes one or more pharmaceutically acceptable excipients, carriers or diluents.
• the particular carrier, diluent or excipient used will depend upon the means and purpose for which the active ingredient is being applied.
• a tablet formulation includes materials such as diluents, binders, lubricants, disintegrants and mixtures thereof.
• Suitable diluents include various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts (e.g., sodium chloride), powdered sugar, and powdered cellulose derivatives.
• examples of diluents or fillers include lactose, mannitol, xylitol, dextrose, sucrose, sorbitol, compressible sugar, microcrystalline cellulose, powdered cellulose, starch, pregelatinized starch, dextrates, dextran, dextrin, dextrose, maltodextrin, calcium carbonate, dibasic calcium-phosphate, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers such as polyethylene oxide and hydroxypropyl methyl cellulose.
• a volume mean diameter drug substance particle size of less than or equal to about 30 microns is preferably utilized.
• Preferred diluents are microcrystalline cellulose (e.g., Avicel® PH102 or PH101 available from FMC Pharmaceutical, Philadelphia, Pa.) and lactose.
• the mean particle size for the microcrystalline cellulose generally ranges from about 90 ⁇ m to about 200 ⁇ m.
• Suitable grades of lactose include anhydrous lactose (about 152 ⁇ m mean), lactose monohydrate and spray dried lactose (e.g., Fast FloTM lactose, about 87 ⁇ m mean, available from Foremost Corp., Baraboo, Wis.).
• the microcrystalline cellulose is present in an amount from about 20 wt % to about 90 wt % and the lactose is present in an amount from about 65 wt % to about 85 wt %.
• a binder may be added.
• Suitable binders include substances such as celluloses (e.g., cellulose, methylcellulose, ethylcellulose, and hydroxymethylcellulose), polypropylpyrrolidone, polyvinylprrolidone, gelatin, gum arabic, polyethylene glycol, starch, sugars (e.g., lactose, sucrose, fructose, and glucose), natural and synthetic gums (e.g., acacia, alginates, and gum arabic) and waxes.
• a lubricant is typically used in a tablet formulation to prevent the tablet and punches from sticking in the die.
• Suitable lubricants include calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
• a preferred lubricant is magnesium stearate.
• the magnesium stearate is generally present in an amount from about 0.25 wt % to about 5.0% wt %.
• Disintegrants may also be added to the composition to break up the dosage form and release the compound.
• Suitable disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, powdered cellulose, lower alkyl-substituted hydroxypropyl cellulose, polacrilin potassium, starch, pregelatinized starch and sodium alginate.
• croscarmellose sodium, lower alkyl-substituted hydroxypropyl cellulose, methyl cellulose and polacrilin potassium are preferred, with croscarmellose sodium being most preferred.
• the croscarmellose sodium is generally present in an amount from about 0.5 wt % to about 5.0 wt %.
• the amount of disintegrant included in the dosage form will depend on several factors, including the properties of-the dispersion, the properties of the porosigen (discussed below), and the properties of the disintegrant selected. Generally, the disintegrant will comprise from 1 wt % to 25 wt %, preferably from 3 wt % to 20 wt % of the dosage form.
• the aqueous coating of the present invention compises a polymer, an opacifier, a plastisizer, a pharmaceutically acceptable diluent/filler and optionally a colorant.
• polymers examples include cellulosics such as hydroxypropyl methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylhydroxyethylcellulose, methylcellulose, and sodium carboxymethylcellulose.
• cellulosics such as hydroxypropyl methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylhydroxyethylcellulose, methylcellulose, and sodium carboxymethylcellulose.
• polymers include vinyls such as polyvinyl pyrrolidone. Of these polymers, the most preferred is hydroxypropyl methylcellulose.
• Examples of opacifiers include titanium dioxide and talc.
• plasticizers include polyhydric alcohols such as glycerol and polyethylene glycols and acetate esters such as glyceryl triacetate (triacetin) and triethyl citrate.
• glidants examples include silicon dioxide, talc and cornstarch.
• compositions of the present invention may include a colorant.
• a colorant is available from a number of commercial vendors and are well known to those skilled in the art.
• Other useful additives include materials such as agents for retarding dissolution (e.g., paraffin), resorption accelerators (e.g., quaternary ammonium compounds), surface active agents (e.g., cetyl alcohol, glycerol monostearate, and sodium lauryl sulfate), adsorptive carriers (e.g., kaolin and bentonite), preservatives, sweeteners, coloring agents, flavoring agents (e.g., citric acid, menthol, glycine or orange powder), stabilizers (e.g., citric acid or sodium citrate), binders (e.g., hydroxypropylmethylcellulose), and mixtures thereof.
• agents for retarding dissolution e.g., paraffin
• resorption accelerators e.g., quaternary ammonium compounds
• surface active agents e.g., cetyl alcohol, glycerol monostearate, and sodium lauryl sulfate
• adsorptive carriers
• the drug substance is not added to the high shear bowl first.
• the typical blending time for the blending in the high shear granulator is from about 10 minutes to about 15 minutes. Although blending times greater than 15 minutes can be used, care, should be taken not to demix the blend.
• the granulator impeller speed is typically run at about 55% to about 65% unit capacity and the chopper is preferably run at the slowest speed setting. Excessive impeller speeds could lead to fluidization of the blend and produce a blend potency loss.
• the active blend is blended in a twin shell “V” or bin blender.
• the typical blending time is about 5 minutes, although small-scale lots have been successfully blended up to about 15 minutes.
• the lubricant is then added to the active blend and blended for about 5 minutes in the twin shell “V” or bin blender.
• silicon dioxide which is a submicron fumed silica prepared by the vapor-phase hydrolysis of a silicon compound, such as silicon tetrachloride.
• colloidal silica is an amorphous powder, which is available commercially from a number of sources, including Cabot Corporation, Boston, Mass.
• colloidal silicon dioxide is also known as colloidal silica, fumed silica, light anhydrous silicic acid, silicic anhydride, and silicon dioxide fumed, among others.
• a variety of commercial grades of colloidal silicon dioxide are produced by varying the manufacturing process. These modifications do not affect the silica content, specific gravity, refractive index, color or amorphous form. However, these modifications are known to change the particle size, surface areas, and bulk densities of the colloidal silicon dioxide products.
• the mean particle size for the silicon dioxide is generally less than or equal to about 15 ⁇ m/bulk density (less than or equal to about 21.0 lbs./ft 3 (336 kg/m 3 )).
• the silicon dioxide is in the form of a dry powder and not a liquid suspension.
• the silicon dioxide is generally present in an amount from about 0.1 to about 2% by weight of the dosage form, preferably, in an amount from about 0.15 to about 1.0% by weight and most preferably in an amount from about 0.10 to about 0.50% by weight of the dosage form.
• Suitable salt derivatives include halides, thiocyanates, sulfates, bisulfates, sulfites, bisulfitesarylsulfonates, alkylsulfates, phosphonates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophbsphonates, alkanoates, cycloalkylalkanoates, arylalkonates, adipates, alginates, aspartates, benzoates, fumarates, glucoheptanoates, glycerophosphates, lactates, maleates, nicotinates, oxalates, palmitates, pectinates, picrates, pivalates, succinates, tartarates, citrates, camphorates, camphorsulfonates, digluconates, trifluoroacetates, and the like.
• a preferred salt of compounds of Formula (I) is tartrate (in particular, D-tartrate) or citrate.
• a preferred compound is lasofoxifene (cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6, 7,8-tetrahydronaphthalen-2-ol).
• the active ingredient is generally present in a pharmaceutical composition in an amount less than or equal to about 14% w/w.
• the active ingredient is typically present in the pharmaceutical composition in an amount less than 4.0% w/w active ingredient, more preferably ⁇ about 0.01% w/w active ingredient and ⁇ 4% w/w active ingredient, even more preferably ⁇ about 0.01% w/w active ingredient and ⁇ about 3.5% w/w active ingredient, most preferably ⁇ about 0.1% w/w active ingredient and ⁇ about 2.5% w/w active ingredient).
• the pharmaceutical composition can be used to produce unit dosage forms containing about 0.05 mg to about 10.0 mg active ingredient per unit dosage, preferably, about 0.1 mg to about 5.0 mg active ingredient per unit dosage.
• the tablet size i.e., unit dosage form
• the tablet size is typically between about 100 mg and 600 mg.
• “low dosage form” refers to a unit dose containing less than about 5.0 mg active ingredient.
• a typical low dosage form contains between about 0.01 and about 5.0 mg active ingredient, preferably between about 0.05 mg and about 4.0 mg, more preferably between about 0.1 mg and about 3.5 mg, most preferably between about 0.1 mg and 2.5 mg.
• the tablet formulation for a 0.25 mg, 0.1 mg and 0.05 mg tablet typically consists of a blend containing about 0.14% w/w active ingredient and the tablet size is varied to achieve the proper dosage; whereas, a 0.5 mg tablet formulation generally contains a blend having about 0.68% w/w active ingredient.
• the concentration of active ingredient in the final pharmaceutical composition is generally adjusted by increasing or decreasing the amount of diluent (e.g., lactose) added to the formulation.
• the tablets are generally prepared by compression in a rotary press. However, the particular method used for tablet formation is non-limiting and is well known to those skilled in the art. After formation of the tablets, the tablets are often coated with one or more coatings.
• the tablet may be coated with a coating to mask flavor, to act as a sealant and/or to act as a receptor for printing a logo or trademark on the tablet surface.
• a common coating is a sugar coating (e.g., sucrose or sorbitol coating).
• the tablet may be coated with a film-forming protecting agent(s) to modify the dissolution properties of the tablet.
• the tablet may be coated with a film-forming coating that resists dissolution for a predictable period of time thus resulting in a delayed or prolonged release of the active ingredient.
• Suitable film-forming protecting agents include celluloses (e.g., hydroxypropyl-methylcellulose, hydroxypropyl cellulose, methylcellulose), polyvinyl pyrrolidone, and ethyl acrylate-methyl methacrylate copolymers.
• the coating formulations may also include additives such as solubilizing agents (e.g., triacetin), preservatives, sweeteners, flavoring agents, coloring agents and other known additives to provide an elegant presentation of the drug.
• the compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation.
• the aqueous coating of the present invention comprises Opadry II® (Y-30-13579-A) and Opadry Clear® (YS-2-19114-A) manufactured by Colorcon, West Point, Pa.
• Opadry II® useful as an opacifying coat, contains lactose monohydrate, hydroxypropyl methyl cellulose, titanium dioxide, triacetin and FD&C Yellow No. 6 aluminum lake.
• Opadry Clear® useful as a polish coat, contains hydroxypropyl methylcellulose and triacetin.
• the active pharmaceutical blend may be filled into hard shell capsules, also referred to as the dry-filled capsule (DFC).
• DFC dry-filled capsule
• the capsule formulation and manufacturing process is similar to the reported tablet core formulation and manufacturing process.
• a hard shell capsule could consist of gelatin and water or hydroxypropyl methylcellulose, water and a gelling agent (gelan gum or carageenan).
• Such capsule compositions do not utilize an aqueous coating.
• the encapsulated pharmaceutical composition comprises about 0.3 to about 14.0 w/w % of lasofoxifene, a prodrug thereof or a pharmaceutically acceptable salt, hydrate or solvate of the compound or the prodrug, about 3.0 w/w % of a disintegrant, about 0.5 w/w % of a glidant, about 1.0 w/w % of a lubricant and about 81.0 w/w % to about 95.0 w/w % of a diluent/filler.
• the pharmaceutical composition may be packaged in a variety of ways.
• an article for distribution includes a container that contains the pharmaceutical composition in an appropriate form.
• Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, foil blister packs, and the like.
• the container may also include a tamper proof, assemblage to prevent indiscreet access to the contents of the package.
• the container typically has deposited thereon a label that describes the contents of the container and any appropriate warnings or instructions.
• compositions containing the compounds of Formula (I) described herein are useful in the treatment or prevention of inter alia breast cancer, osteoporosis, obesity, cardiovascular disease, hypercholesterolemia, endometriosis and prostatic disease. Accordingly, the pharmaceutical formulations and processes described herein containing the compounds of Formula (I) may be used in the manufacture of a medicament for the therapeutic applications described above.
• a therapeutically effective amount of the manufactured medicament may be administered to a human in need of such treatment or prevention.
• the term “therapeutically effective amount” refers to an amount of active ingredient which is capable of inhibiting or preventing the various pathological conditions or symptoms thereof and sequelae, referred to above.
• the terms “inhibit” or “inhibiting” refers to prohibiting, treating, alleviating, ameliorating, halting, restraining, slowing or reversing the progression, or reducing the severity of a pathological condition or symptom related to or resultant from the respective condition being treated.
• the pharmaceutical formulations may be used for both medical therapeutic (acute or chronic) and/or prophylactic (prevention) administration as appropriate.
• the dose, frequency and duration will vary depending on such factors as the nature and severity of the condition being treated, the age and general health of the host and the tolerance of the host to the active ingredient.
• the pharmaceutical composition or medicament may be given in a single daily dose, in multiple doses during the day or even in a weekly dose.
• the regimen may last from about 2-3 days to several weeks or longer.
• the composition is administered to a human patient once a day with a unit dosage of about 0.25 mg to about 10.0 mg, but the above dosage may be properly varied depending on the age, body weight and medical condition of the patient and the type of administration.
• lasofoxifene may be prepared using the procedures described below.
• the aqueous layer was further washed with Et 2 O (2x).
• the combined organic layers were dried (MgSO 4 ), filtered, and concentrated to provide 6-methoxy-1-tetralone (22 g).
• the aqueous layer was basified to pH 12 with 5 N NaOH and 15% aqueous (NH 4 ) 2 CO 3 , (1000 mL) was added.
• the aqueous mixture was extracted with CH 2 Cl 2 (2x).
• the organic solution was dried (MgSO 4 ), filtered, and concentrated to provide a brown oil. Impurities were distilled off (110°-140° C. @0.2 mmHg) to yield the product (74 g, 57%).
• the hydrobromide salt (9.6 g, 69%) was dissolved in CHCl 3 /MeOH and was stirred with saturated NaHCO 3 (aq). The layers were separated and the aqueous layer was further extracted with CHCl 3 /MeOH. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated to yield product as an off-white foam.
• Example 1 The following materials used in Example 1 may be obtained from the corresponding sources listed below: Avicel TM PH101 FMC Pharmaceutical (Philadelphia, PA) (microcrystalline cellulose) Lactose Fast Flo TM 316 Foremost Corp. (Baraboo, WI) magnesium stearate Mallinckrodt (St. Louis, MO) hydroxypropyl cellulose Hercules Inc. (Hopewell, VA) sodium croscarmellose FMC Pharmaceutical (Philadelphia, PA) ⁇ -cyclodextrin sulfobutyl ether Prepared using the method described in U.S. Pat. No. 6,153,746 silicon dioxide Grace Davison (Columbia, MD) ProSolv TM 50 Penwest, Patterson, NJ (silicified microcrystalline cellulose)
• the mixture was blended for approximately 15 minutes. While blending, an appropriate amount of water (approximately 63% w/w of dry blend) was added over a 8.5 minute period and then allowed to continue blending for an additional 30 seconds to achieve the desired wet mass. The wet mass was then dried to a moisture level less than about 2% under vacuum (about 50 millibar (mB)). The dried granulation was milled through a conical mill fitted with a 0.04 inch (0.10 cm) screen and round edge impeller set at 1750 rpm speed. The mixture was blended for about 10 minutes in a 150 cc glass bottle on a Turbula mixer. Magnesium stearate (0.125 g) was added to the mixture and then blended for about 5 minutes. The active blend was then compressed into tablets using a KilianTM T100 tablet press (available from Kilian & Co., Inc., Horsham, Pa.).
• KilianTM T100 tablet press available from Kilian & Co., Inc., Horsham, Pa.
• the mixture was blended for about 2 minutes. While blending, the lasofoxifene:water solution was added over a 3 minute period. The wet mass was then dried to a moisture level of less than about 1% in a 50° C. forced hot air oven. The dried granulation was passed through a conical mill fitted with a 0.055 inch (0.14 cm) screen and round edge impeller set at 1750 rpm speed. Magnesium stearate (0.125 g) was added to the mixture and then blended for about 5 minutes. The active blend was then compressed into tablets using a ManestyTM F-Press tablet press (available from Thomas Engineering Inc., Hoffman Estates, Ill.).
• the lactose, microcrystalline cellulose, croscarmellose sodium and silicon dioxide were blended for 5 minutes.
• the lasofoxifene was added next and blended for about 15 minutes.
• the active blend was then discharged from the high shear blender and blended for about 5 minutes in a twin shell “V” blender.
• Magnesium stearate (7.50 g) was added to the active blend and blended for about 5 minutes.
• the active blend was roller compacted on a Vector FreundTM roller compactor unit and milled through a rotating granulator fitted with a 0.033′′ (0.084 cm) screen (both available from Vector Corp., Marion, Iowa).
• the active granulation was blended for about 5 minutes in a twin shell “V” blender.
• Another portion of magnesium stearate (7.50 g) was added to the granulation and blended for about 5 minutes.
• the final blend was compressed into tablets on a KilianTM T100 rotary press.
• the components of the lasofoxifene formulation were selected based on in-vivo and manufacturing performance and chemical stability.
• the drug substance has been shown to be susceptible to oxidation due to the presence of free radicals or the presence of metal impurities, which could indirectly lead to free radical formation through chelation.
• the disintegrant, croscarmellose sodium was proven to be chemically more stable with the drug substance than other disintegrants such as sodium starch glycolate or polyvinylpyrrolidone.
• the tablet film coating system was also designed to minimize oxidative degradation through the selection of plasticizer.
• Triacetin is the plasticizer of choice based on chemical stability and was proven to be more stable than other plasticizers such as polyethylene glycol.
• Table 1 summarizes the stability results by high-pressure liquid chromatography observed for the three different processes. TABLE I Comparison of Lasofoxifene Stability Conventional Wet Drug In Solution Manufacturing Granulation Wet Granulation Process Dry Granulation (comparative) (comparative) Percent Drug 0.14 0.28 0.068 Load Total Percent 0.02 Not Available 0.95 Initial Impurities Total Percent 0.13 at 12 months 0.54 at 6 weeks 1.43 at 6 weeks Impurities at 5° C. Total Percent 0.13 at 12 months 1.21 at 6 weeks 2.03 at 6 weeks Impurities at 30° C. Total Percent 0.41 at 6 months 4.3 at 6 weeks 3.10 at 6 weeks Impurities at 40° C./ 75% RH Total Percent 0.39 at 6 months 5.26 at 6 weeks 4.25 at 6 weeks Impurities at 50° C.
• Table III summarizes the stability results of film coated lasofoxifene tablet formulations. TABLE III Comparison of Lasofoxifene Film Coated Tablet Stability Percent Drug Load 1.42 0.34 Film Coat Plasticizer Polyethylene Glycol Triacetin Total Percent Impurities at 0.06 at 12 weeks 0.08 at 6 months 5° C. Total Percent Impurities at 0.34 at 12 weeks 0.2 at 6 months 30° C. Total Percent Impurities at 1.74 at 12 weeks 0.2 at 6 months 40° C./75% RH
• Tablet cores were film coated in an appropriate size film-coating unit. The appropriate amount of opacifying and polishing film coats was applied to the tablets.
• Control 1 tablets were formed using conventional immediate release dosage form tableting excipients.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Physical Education & Sports Medicine (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Child & Adolescent Psychology (AREA)
• Cardiology (AREA)
• Reproductive Health (AREA)
• Urology & Nephrology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=30115812

Family Applications (2)

Family Applications After (1)

Country Status (36)

Cited By (11)

Families Citing this family (15)

Citations (2)

Family Cites Families (12)

• 2003
  • 2003-06-23 PA PA20038576201A patent/PA8576201A1/es unknown
  • 2003-06-30 WO PCT/IB2003/003074 patent/WO2004006895A1/en not_active Application Discontinuation
  • 2003-06-30 CA CA002489407A patent/CA2489407C/en not_active Expired - Fee Related
  • 2003-06-30 MX MXPA05000394A patent/MXPA05000394A/es active IP Right Grant
  • 2003-06-30 AT AT03764059T patent/ATE550017T1/de active
  • 2003-06-30 NZ NZ537278A patent/NZ537278A/en unknown
  • 2003-06-30 AU AU2003247017A patent/AU2003247017B2/en not_active Ceased
  • 2003-06-30 PT PT03764059T patent/PT1534248E/pt unknown
  • 2003-06-30 PL PL03374913A patent/PL374913A1/xx not_active Application Discontinuation
  • 2003-06-30 JP JP2004521001A patent/JP4446446B2/ja not_active Expired - Fee Related
  • 2003-06-30 SI SI200332150T patent/SI1534248T1/sl unknown
  • 2003-06-30 EP EP03764059A patent/EP1534248B1/en not_active Expired - Lifetime
  • 2003-06-30 CN CNB038162881A patent/CN100344278C/zh not_active Expired - Fee Related
  • 2003-06-30 BR BR0312563-7A patent/BR0312563A/pt not_active IP Right Cessation
  • 2003-06-30 DK DK03764059.6T patent/DK1534248T3/da active
  • 2003-06-30 IL IL16574603A patent/IL165746A0/xx unknown
  • 2003-06-30 KR KR1020057000369A patent/KR100782693B1/ko active IP Right Grant
  • 2003-06-30 AP AP2005003201A patent/AP2005003201A0/xx unknown
  • 2003-06-30 EA EA200401583A patent/EA007268B1/ru not_active IP Right Cessation
  • 2003-06-30 OA OA1200500007A patent/OA12883A/en unknown
  • 2003-06-30 ES ES03764059T patent/ES2395123T3/es not_active Expired - Lifetime
  • 2003-07-01 US US10/612,679 patent/US20040057992A1/en not_active Abandoned
  • 2003-07-04 TW TW092118389A patent/TW200406222A/zh unknown
  • 2003-07-07 PE PE2003000682A patent/PE20040104A1/es not_active Application Discontinuation
  • 2003-07-07 HN HN2003000206A patent/HN2003000206A/es unknown
  • 2003-07-08 UY UY27886A patent/UY27886A1/es not_active Application Discontinuation
  • 2003-07-08 AR AR20030102454A patent/AR040434A1/es not_active Application Discontinuation
• 2004
  • 2004-12-13 IL IL165746A patent/IL165746A/en active IP Right Grant
  • 2004-12-13 IS IS7594A patent/IS7594A/is unknown
  • 2004-12-17 HR HR20041196A patent/HRP20041196A2/hr not_active Application Discontinuation
  • 2004-12-17 ZA ZA200410196A patent/ZA200410196B/en unknown
• 2005
  • 2005-01-03 NO NO20050018A patent/NO20050018L/no not_active Application Discontinuation
  • 2005-01-10 MA MA28036A patent/MA27318A1/fr unknown
  • 2005-01-10 EC EC2005005528A patent/ECSP055528A/es unknown
  • 2005-01-10 TN TNP2005000006A patent/TNSN05006A1/fr unknown
  • 2005-11-04 HK HK05109850A patent/HK1077747A1/xx not_active IP Right Cessation
• 2006
  • 2006-11-09 JP JP2006303440A patent/JP2007031451A/ja active Pending
  • 2006-12-22 US US11/615,511 patent/US7553500B2/en not_active Expired - Fee Related
• 2012
  • 2012-06-06 CY CY20121100504T patent/CY1112892T1/el unknown

Patent Citations (3)

Also Published As

Similar Documents

Legal Events